3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
9
Carcinoma, Transitional Cell
4
Neoplasms
3
Neoplasm Metastasis
3
Breast Neoplasms
3
Ureteral Neoplasms
2
Urothelial Cancer
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Renal Insufficiency
1
Recurrence
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Locally Advanced or Metastatic Unresectable Urothelial Cancer
1
Kidney Neoplasms
1
Interventions
Mitomycin
3
Abiraterone Acetate
3
motexafin gadolinium
2
abiraterone
2
Suspensions
2
Sunitinib
2
Powders
2
Paclitaxel
2
Gemcitabine
2
Drug Therapy
2
Docetaxel
2
vinflunine
1
valrubicin
1
temsirolimus
1
sipuleucel-T
1
pembrolizumab
1
palbociclib
1
onapristone
1
olaparib
1
niraparib
1
luprolide acetate gel depot
1
gallium 68 PSMA-11
1
enfortumab vedotin
1
darolutamide
1
atezolizumab
1
apalutamide
1
abemaciclib
1
Watchful Waiting
1
Transurethral Resection of Prostate
1
Tinzaparin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Urogenital Neoplasms
×
vinflunine
×
Clear all
NCT01599013
2015-12-08
JASINT1
Pierre Fabre Medicament
Phase 2
Completed
69 enrolled